Modulation of IL-4 level by fludarabine and its relation to apoptosis in chronic B-cell lymphocytic leukemia.

Abstract

UNLABELLED:

Accumulation of malignant B-lymphocytes in chronic B-cell lymphocytic leukemia (B-CLL) is mainly attributed to reduced apoptosis rather than increased proliferation rate. Interleukin-4 (IL-4) has been proved to be involved in the survival mechanisms of B-cells as well as protection of B-CLL cells against spontaneous or drug induced apoptosis. Fludarabine is one of purine analogs and the current standard treatment for B-CLL, which has been proved to induce apoptosis in normal and malignant lymphocytes. We investigated the effect of ex vivo treatment of peripheral blood lymphocytes (PBLs) with Fludarabine on apoptosis and IL-4 production in untreated patients with B-CLL. The study was conducted on 15 recently diagnosed B-CLL patients and 15 normal healthy control subjects. PBLs were isolated and cultured in complete culture media without and with the addition of 1 microM/ml Fludarabine for 48 hrs. Harvested cells were assessed by flowcytometry for apoptosis and IL-4 production using staining with Annexin-V/PI and specific monoclonal IL-4 antibody, respectively.

RESULTS:

Fludarabine significantly increased the rate of in vitro PBLs' apoptosis in both B-CLL patients and normal subjects (3.81 +/- 1.98% and 4.11 +/- 2.14% without Fludarabine vs 14.78 +/- 7.83% and 9.99 +/- 5.60% with Fludarabine, respectively). However, the cytotoxic effect of Fludarabine was significantly higher in B-CLL patients than normal control subjects. Cytolasmic IL-4 content, as reflected by mean flouresence intensity (MFI), as well as percentage of IL-4+ve PBLs in absence Fludarabine were nearly the same both in B-CLL patients (20.28 +/- 14.34 & 2.97 +/- 1.48%, respectively) and normal subjects (27.75 +/- 14.44 & 2.58 +/- 1.27% respectively), with no significant difference. Corresponding values were significantly increased in both B-CLL patients (34.46 +/- 22.95 & 15.08 +/- 8.17%, respectively) and normal subjects (40.15 +/- 17.11 & 17.05 +/- 8.74%, respectively) when PBLs were co-cultured with Fludarabine. However, no significant difference was observed when studied groups were compared to each other. No correlation was observed between the intracellular IL-4 content or percentage of IL-4+ve PBLs and Fludarabine-induced apoptosis. In conclusion, Floudarabine could induce apoptosis and IL-4 production in B-CLL patients. Further studies on large cohort population is recommended to clarify the apoptotic effect of Fludarabine.

• Authors: Lobna A Abou Shamaa, Amina El-Sayed Hussein, Ola A Balbaa, Nahla M Farahat, Mohamed Abd El-Wahid Ali
• Journal: The Egyptian journal of immunology (Egypt J Immunol) Vol. 15 Issue 1 Pg. 181-92 ( 2008) ISSN: 1110-4902 [Print] Egypt
• PMID: 20306682 (Publication Type: Journal Article)

Chemical References

• Hemoglobins
• IL4 protein, human
• Interleukin-4
• Vidarabine
• fludarabine

Topics

• Aged
• Apoptosis (drug effects)
• Female
• Hemoglobins (analysis)
• Humans
• Interleukin-4 (metabolism)
• Leukemia, Lymphocytic, Chronic, B-Cell (blood, diagnosis, metabolism, pathology)
• Leukocyte Count
• Leukocytes, Mononuclear (drug effects, metabolism, pathology)
• Lymphocyte Count
• Male
• Middle Aged
• Neoplasm Staging
• Platelet Count
• Vidarabine (analogs & derivatives, pharmacology)